Dow Today: Pfizer (PFE) Higher

The Dow Jones Industrial Average ( ^DJI) is trading up 40 points (+0.3%) at 12,947 as of Friday, Mar 9, 2012, 1:40 p.m. ET. During this time, 333.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 818.6 million. The NYSE advances/declines ratio sits at 2,229 issues advancing vs. 691 declining with 116 unchanged.

The Dow component leading the way higher looks to be Pfizer (NYSE: PFE), which is sporting a four-cent gain (+0.2%) bringing the stock to $21.50. This single gain is lifting the Dow Jones Industrial Average by 0.3 points or roughly accounting for 0.8% of the Dow's overall gain. Volume for Pfizer currently sits at 22.8 million shares traded vs. an average daily trading volume of 43.5 million shares.

Pfizer has a market cap of $166.5 billion and is part of the health care sector and drugs industry. Shares are down 0.9% year to date as of Thursday's close. The stock's dividend yield sits at 4.1%.

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company has a P/E ratio of 19.3, above the average drugs industry P/E ratio of 14.9 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
null

If you liked this article you might like

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign